Adiso Therapeutics

[Not Yet Scheduled]
Adiso is an innovative, clinical-stage biopharmaceutical company dedicated to improving the health of patients suffering from debilitating inflammatory diseases. Adiso has three distinct candidates that may change the treatment paradigm for inflammatory diseases: ADS051, an oral gut-restricted modulator of neutrophil trafficking and activation; ADS024, an oral single strain live biotherapeutic product (SSLBP); and ADS032 a dual NLRP1/NLRP3 inflammasome inhibitor.

Adiso has built these programs upon a rich history of institutional and academic collaboration, including the University College Cork, Ireland, the APC Microbiome Institute, the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia and the University of Edinburgh Centre for Inflammation Research.

Adiso was founded in 2022 and is based in Concord, MA,
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2022
Main Therapeutic Focus:
Lead Product in Development:
ADS024, followed by ADS051 and ADS032
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO
Adiso Therapeutics